SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in...
68 insider purchases on record · latest filing 2024-09-16.
Insiders have also filed 4 sale transactions at SCYX.